Exploring cell and gene therapies

Cell and gene therapy companies continue to attract large deals in 2022, despite the financing landscape looking gloomier than in the previous year.

Shape Therapeutics is developing next-generation gene-therapy technologies that harness the power of artificial intelligence and RNA editing to repair disease-causing mutations.

By coupling Twist Bioscience’s DNA-writing technology with expertise in antibody engineering, Twist Biopharma can accelerate the development of new biologics and cell therapies.

Precision BioSciences is transforming drug development for new, potentially first- and best-in-class cell and gene therapies with its proprietary ARCUS gene-editing platform, which is derived from a small, naturally occurring DNA-editing nuclease.

Regenerative medicine company Locate Bio is aiming to transform the musculoskeletal market with its range of therapeutic orthobiologic products.

Minaris Regenerative Medicine is developing large-scale 3D cell-production processes and optimizing its culture parameters, as well as enabling in-house batch certification, to enable its partners to realize the huge potential of cell therapies.

Asgard Therapeutics is moving cancer immunotherapy forward with an off-the-shelf direct cell reprogramming platform that turns cancer cells into immunogenic dendritic cells that induce potent anticancer immunity.